Susquehanna International Group’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.33M | Buy |
149,700
+51,200
| +52% | +$1.22M | ﹤0.01% | 5056 |
|
|
2025
Q4 | $2.63M | Sell |
98,500
-249,200
| -72% | -$5.96M | ﹤0.01% | 5115 |
|
|
2025
Q3 | $7.42M | Buy |
347,700
+137,500
| +65% | +$3.25M | ﹤0.01% | 3459 |
|
|
2025
Q2 | $4.53M | Buy |
210,200
+71,500
| +52% | +$1.33M | ﹤0.01% | 4153 |
|
|
2025
Q1 | $2.3M | Sell |
138,700
-505,100
| -78% | -$9.18M | ﹤0.01% | 5210 |
|
|
2024
Q4 | $11.8M | Sell |
643,800
-11,300
| -2% | -$182K | ﹤0.01% | 2455 |
|
|
2024
Q3 | $10.1M | Buy |
655,100
+474,700
| +263% | +$7.92M | ﹤0.01% | 2598 |
|
|
2024
Q2 | $2.93M | Sell |
180,400
-176,800
| -49% | -$2.85M | ﹤0.01% | 4362 |
|
|
2024
Q1 | $6.6M | Buy |
357,200
+209,300
| +142% | +$5.19M | ﹤0.01% | 3200 |
|
|
2023
Q4 | $4.63M | Sell |
147,900
-69,800
| -32% | -$1.67M | ﹤0.01% | 3834 |
|
|
2023
Q3 | $4.54M | Buy |
217,700
+118,600
| +120% | +$3.22M | ﹤0.01% | 3704 |
|
|
2023
Q2 | $2.37M | Buy |
99,100
+3,700
| +4% | +$82.2K | ﹤0.01% | 4802 |
|
|
2023
Q1 | $1.8M | Buy |
95,400
+19,000
| +25% | +$362K | ﹤0.01% | 5374 |
|
|
2022
Q4 | $1.22M | Sell |
76,400
-28,900
| -27% | -$452K | ﹤0.01% | 5764 |
|
|
2022
Q3 | $1.72M | Sell |
105,300
-214,800
| -67% | -$3.48M | ﹤0.01% | 5250 |
|
|
2022
Q2 | $4.51M | Sell |
320,100
-124,900
| -28% | -$2.33M | ﹤0.01% | 3344 |
|
|
2022
Q1 | $10.8M | Sell |
445,000
-198,500
| -31% | -$4.8M | ﹤0.01% | 2460 |
|
|
2021
Q4 | $15M | Buy |
643,500
+419,000
| +187% | +$8.43M | ﹤0.01% | 2176 |
|
|
2021
Q3 | $3.73M | Buy |
224,500
+10,200
| +5% | +$197K | ﹤0.01% | 4497 |
|
|
2021
Q2 | $5.23M | Sell |
214,300
-248,700
| -54% | -$5.61M | ﹤0.01% | 3967 |
|
|
2021
Q1 | $11.9M | Buy |
463,000
+230,300
| +99% | +$10.1M | ﹤0.01% | 2512 |
|
|
2020
Q4 | $12.4M | Buy |
232,700
+49,800
| +27% | +$2.47M | ﹤0.01% | 2248 |
|
|
2020
Q3 | $7.54M | Sell |
182,900
-123,400
| -40% | -$5.33M | ﹤0.01% | 2550 |
|
|
2020
Q2 | $14.8M | Buy |
306,300
+63,500
| +26% | +$3.05M | ﹤0.01% | 1709 |
|
|
2020
Q1 | $10.3M | Sell |
242,800
-128,700
| -35% | -$5.3M | ﹤0.01% | 1717 |
|
|
2019
Q4 | $15.9M | Sell |
371,500
-146,700
| -28% | -$6.38M | ﹤0.01% | 1638 |
|
|
2019
Q3 | $18.6M | Buy |
518,200
+55,000
| +12% | +$1.67M | 0.01% | 1390 |
|
|
2019
Q2 | $12.4M | Sell |
463,200
-112,500
| -20% | -$2.87M | ﹤0.01% | 1689 |
|
|
2019
Q1 | $15.5M | Sell |
575,700
-324,800
| -36% | -$7.59M | 0.01% | 1381 |
|
|
2018
Q4 | $14.6M | Sell |
900,500
-14,900
| -2% | -$289K | 0.01% | 1296 |
|
|
2018
Q3 | $19M | Buy |
915,400
+617,800
| +208% | +$9.72M | 0.01% | 1362 |
|
|
2018
Q2 | $4.54M | Sell |
297,600
-375,600
| -56% | -$6.7M | ﹤0.01% | 2828 |
|
|
2018
Q1 | $15.1M | Buy |
673,200
+443,100
| +193% | +$12.3M | 0.01% | 1440 |
|
|
2017
Q4 | $6.93M | Sell |
230,100
-199,200
| -46% | -$6.37M | ﹤0.01% | 2169 |
|
|
2017
Q3 | $16.2M | Buy |
429,300
+185,400
| +76% | +$6.03M | 0.01% | 1389 |
|
|
2017
Q2 | $6.8M | Sell |
243,900
-253,500
| -51% | -$7.55M | ﹤0.01% | 2052 |
|
|
2017
Q1 | $17.1M | Sell |
497,400
-69,300
| -12% | -$2.45M | 0.01% | 1192 |
|
|
2016
Q4 | $16.3M | Buy |
566,700
+12,100
| +2% | +$320K | 0.01% | 1194 |
|
|
2016
Q3 | $17.6M | Buy |
554,600
+12,500
| +2% | +$424K | 0.01% | 1109 |
|
|
2016
Q2 | $17.6M | Sell |
542,100
-234,000
| -30% | -$7.83M | 0.01% | 1060 |
|
|
2016
Q1 | $21.7M | Buy |
776,100
+222,200
| +40% | +$4.85M | 0.01% | 944 |
|
|
2015
Q4 | $19.7M | Buy |
553,900
+288,600
| +109% | +$10.2M | 0.01% | 1159 |
|
|
2015
Q3 | $8.77M | Buy |
265,300
+40,100
| +18% | +$1.67M | ﹤0.01% | 1981 |
|
|
2015
Q2 | $9.43M | Sell |
225,200
-164,100
| -42% | -$6.35M | ﹤0.01% | 2071 |
|
|
2015
Q1 | $12.7M | Buy |
389,300
+83,000
| +27% | +$2.85M | 0.01% | 1635 |
|
|
2014
Q4 | $9.72M | Sell |
306,300
-467,000
| -60% | -$13.2M | ﹤0.01% | 2068 |
|
|
2014
Q3 | $19.1M | Sell |
773,300
-124,200
| -14% | -$2.9M | 0.01% | 1458 |
|
|
2014
Q2 | $20.3M | Sell |
897,500
-65,500
| -7% | -$1.37M | 0.01% | 1388 |
|
|
2014
Q1 | $23.4M | Buy |
963,000
+274,600
| +40% | +$6.95M | 0.01% | 1136 |
|
|
2013
Q4 | $17.2M | Buy |
688,400
+9,100
| +1% | +$215K | 0.01% | 1504 |
|
|
2013
Q3 | $18.7M | Buy |
679,300
+59,000
| +10% | +$1.23M | 0.01% | 1267 |
|
|
2013
Q2 | $11.3M | Buy |
+620,300
| New | +$8.54M | 0.01% | 1653 |
|
Other funds holding ACAD
BBA
VPM
RI
VCM
PAI
Susquehanna International Group's ACAD Position: Q1 2026 in Review
Susquehanna International Group increased its Acadia Pharmaceuticals (ACAD) stake by 117% in Q1 2026, buying an estimated $577K and bringing the position to 44,792 shares worth $997K. The position accounts for ﹤0.01% of the portfolio, ranked #7897.
Susquehanna International Group first reported a position in ACAD in Q2 2013 and has held it in 50 quarters since. The position peaked at $32.3M in Q4 2014. 342 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.
- Susquehanna International Group held 44,792 shares of Acadia Pharmaceuticals worth $997K as of Q1 2026.
- Susquehanna International Group bought 24,140 Acadia Pharmaceuticals shares in Q1 2026, an estimated $577K.
- Acadia Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #7897 holding.
- Susquehanna International Group first reported a position in Acadia Pharmaceuticals in Q2 2013 and has held it in 50 quarters since.
- Susquehanna International Group's Acadia Pharmaceuticals position peaked at $32.3M in Q4 2014.
- 342 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.
Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.